)
Visual
test
Personalis
Personalis (PSNL) investor relations material
Personalis Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary4 Nov, 2025
Executive summary
Achieved 4,388 clinical tests in Q3 2025, up 26% sequentially and 364% year-over-year, driven by strong physician adoption of NeXT Personal for cancer monitoring.
Q3 2025 revenue was $14.5 million, down 44% year-over-year, mainly due to declines in Natera, population sequencing, and pharma test revenues.
Net loss for Q3 2025 was $21.7 million, improved from $39.1 million last year, which included a $26 million non-cash warrant expense.
Strategic focus on clinical adoption, reimbursement, and expansion of Tempus partnership to colorectal cancer, with exclusivity extended to December 2028.
Three MolDX dossiers for Medicare coverage under review, targeting two coverage decisions by year-end.
Financial highlights
Q3 2025 revenue: $14.5 million (down from $25.7 million in Q3 2024); nine-month revenue: $52.3 million (down from $67.8 million in 2024).
Biopharma/pharma revenue: $13.1–$13.2 million, down 16% year-over-year, with NeXT Personal MRD revenue accounting for over one-third.
Gross margin: 13.2% in Q3 2025, down from 34% year-over-year, mainly due to lower revenue and higher clinical test costs ahead of reimbursement.
Operating expenses: $25.2 million, up from $23.1 million year-over-year, driven by higher selling expenses.
Cash and short-term investments: $150.5 million at quarter-end, with $23.4 million used in Q3 operations and capex.
Outlook and guidance
Full-year 2025 revenue guidance revised to $68–$73 million (previously $70–$80 million); Q4 2025 revenue expected between $15.7 million and $20.7 million.
Pharma and other customer revenue expected at $50–$54 million; population sequencing and enterprise sales at $16.5–$17 million.
Clinical test reimbursed revenue guidance lowered to $1.5–$2 million due to pending reimbursement approvals.
Gross margin expected at 22%–24%; net loss of ~$85 million; cash usage ~$75 million for the year.
Current cash and investments expected to fund operations for at least the next 12 months.
How does delayed reimbursement affect cash burn?
What drives the population sequencing increase?
CATE trial's role in evidence base
Impact of customs delays on Q4 biopharma revenue
MolDX review status for 2025 coverage targets
Clinical volume growth vs. cash burn strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 7 FebSBIN
Q3 FY26 net profit hit ₹21,028.15 crore, driven by robust growth and strategic divestments. - 7 FebGICRE
Net profit for the nine months surged to ₹6,62,217 lakhs, with a robust solvency ratio of 3.87. - 7 Feb517271
Strong revenue and profit growth, interim dividend, and major investments approved. - 7 Feb514167
Quarterly and nine-month results reflect solid revenue, profit, and compliance with new labour codes. - 7 FebMGL
Strong revenue growth offset by lower margins and profit; interim dividend declared. - 7 FebPGIL
Strong revenue and margin growth, with India set for further expansion and upgraded ratings. - 7 Feb504614
Strong revenue and profit growth in Q3 FY26, led by power and steel segments. - 7 FebCHEMPLASTS
Net losses widened and revenue fell year-over-year amid regulatory and market headwinds. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus.
Next Personalis earnings date
Q4 202527 Feb, 2026
Personalis
Next Personalis earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Personalis Inc is a biotechnology company that provides genomic sequencing and analytics services for cancer and other complex diseases. The company offers advanced molecular testing for research and clinical applications, including personalized cancer therapies and biomarker discovery. Personalis Inc is headquartered in Fremont, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage